Company Information

  

Address: 4550 TOWNE CENTRE COURT  
City: SAN DIEGO 
State: CA 
Zip Code: 92121 
Telephone: 858-207-4264 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II), formerly known as LJPC-501, was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is our first commercial product. LJPC-401, a clinical-stage investigational product, is our proprietary formulation of synthetic human hepcidin. LJPC-401 is being developed for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-7.17NAN/E
03/2018-6.37NAN/E
12/2017-5.41NAN/E
09/2017-5.09NAN/E
06/2017-5.14NAN/E
03/2017-4.84NAN/E
12/2016-4.54NAN/E
09/2016-3.79NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.14Total Liab/Total Assets0.26
Net Inc/Total Assets-0.96Total Liab/Inv Cap0.31
Net Inc/Inv Cap-1.14Total Liab/Comm Equity0.04
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio5.07
Inventory TurnoverNACurrent Ratio5.07
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 1.59 0.81 0.00 0.00
Cost of Goods Sold 0.13 0.06 NA 0.00
Selling & Admin Exps 22.16 23.02 11.94 7.39
Operating Income -51.57 -50.69 -38.85 -26.48
Interest Exp NA NA NA NA
Pretax Income -52.78 -50.53 -38.55 -26.29
Other Income NA 0.17 0.30 NA
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -52.78 -50.53 -38.55 -26.29

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 241.43 154.41 90.92 121.75
Receivables - Total 0.37 NA NA NA
Inventories - Total 0.94 0.82 NA NA
Total Current Assets 248.02 161.55 94.06 123.52
Net Property, Plant & Equipment 24.21 24.44 24.57 6.53
Total Assets 273.14 186.90 119.54 130.06
Liabilities        
Accounts Payable 17.64 14.65 17.18 10.26
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 19.01 16.02 18.55 10.26
Long-Term Debt NA NA NA NA
Total Liabilities 157.47 29.49 31.34 10.26
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 6.64 6.64 6.64 6.64
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -824.82 -772.04 -721.51 -682.97
Treasury Stock NA NA NA NA
Total Stockholders' Equity 115.67 157.41 88.20 119.80
Total Liabilities and Stockholders' Equity 273.14 186.90 119.54 130.06

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -37.57 -45.85 -24.44 -19.21
Net Cash Provided by Investing Activities -0.89 -0.99 -4.91 -2.27
Net Cash Provided by Financing Activities 125.48 110.34 -0.58 0.29

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-17.93-2062.00
12/20140.00-21.31-2.00
12/20151.06-41.91-2.68
12/20160.62-78.18-4.54
12/20170.00-114.80-5.41
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1811730,576--




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.